LQDA files 8-K — Item 2.02 Results of Operations

Liquidia Corporation (LQDA), a $3.7B market-cap biopharmaceutical company, filed an 8-K with the SEC disclosing Item 2.02 (Results of Operations and Financial Condition) on May 11, 2026 at 06:45:35 ET, per EDGAR accession number 0001104659-26-058234.

What Was Filed

Item 2.02 is the SEC’s standardized category for public announcements of quarterly or annual operating results and financial condition. The filing was submitted concurrently with LQDA’s Q1 2026 10-Q quarterly report, per separate SEC filings on the same date. The 8-K includes Exhibit 99.1, the official supporting earnings announcement document for the period.

The Disclosure

Per SEC rules, Item 2.02 filings for biopharmaceutical firms typically accompany an official earnings press release, summarizing quarterly financial performance, key operational milestones, and often updated full-year financial guidance. This filing aligns with the previously announced May 11, 2026, Q1 2026 earnings announcement date, confirming the exhibit contains the formal quarterly results update for the first three months of 2026.

Cross-Referenced Prior Signals

This filing follows a series of recent open-market share sales by LQDA’s CEO, Jeffs Roger. On May 7, 2026, Roger sold 75,000 shares in three separate tranches at prices ranging from $40.10 to $42.09, generating $3.07 million in gross proceeds, just four days prior to the 8-K filing. He had also sold 43,300 shares across three transactions in April 2026, bringing his total 2026 year-to-date open-market sales to 118,300 shares. Additionally, analyst ratings for LQDA have remained completely static since February 2026, with a split of 1 Strong Buy, 7 Buy, and 1 Sell rating across covering firms, with no adjustments announced as of May 1, 2026. As of December 31, 2025, 71.6% of LQDA’s float was held by 254 institutional investors, a 21-firm increase from the prior quarter.

What This Filing Does NOT Disclose

First, verified Q1 2026 GAAP and non-GAAP EPS and total revenue figures: the provided research context only lists consensus estimates ($0.406 EPS, $119.4M revenue) with no actual results disclosed here. Second, segment-specific revenue breakdown for YUTREPIA, LQDA’s only commercialized product candidate for pulmonary arterial hypertension, a key metric for investors valuing the firm’s commercial traction. Third, updated 2026 financial guidance, a common addition to Item 2.02 earnings releases for public biopharmaceutical companies that is not confirmed to be included in this filing.